INTRODUCTION
A compelling body of evidence indicates that the presence of lymphocytotoxic antibodies in the sera of prospective recipients of kidney transplants subsequently affects graft survival unfavorably (1) . Sometimes these antibodies can be detected only when the sensitivity of the lymphocytotoxic test is increased by prolonging the incubation time, adding sublytic amounts of rabbit antiDr. Ferrone is a Visiting Scientist from the University of Milan, Italy.
Received for pulblication 29 July 1974 and in revised form 7 October 1974. human lymphocyte serum to the reaction mixture, or using lymphocytes treated with trypsin as target cells (2) . There remains, however, a certain percentage of patients who reject their kidney transplants acutely, even though no cytotoxic antibodies to peripheral lymphocytes are detected by any of the above means. In an attempt to determine whether these patients do indeed have cytotoxic antibodies that play a role in the rejection of the grafts, we have screened a number of sera from prospective recipients of kidney transplants against a panel of cultured human lymphoid cells and correlated the results with graft survival. Cultured human lymphoid cells are more sensitive than peripheral lymphocytes to HL-A antibody-mediated lysis because the former elicit higher titers of HL-A alloantisera (3, 4) and are lysed by human complement activated by HL-A antibodies (5) ; human serum, though, is a poor source of complement when peripheral lymphocytes are the targets (5) . Although cultured lymphoid cells have more antigenic determinants than peripheral lymphocytes (6, 7) , the reason for their greater sensitivity is not completely clear. Cultured cells may also have determinants not found on peripheral lymphocytes (3, (8) (9) (10) (11) To reduce loss of complement activity, the absorption of rabbit serum was performed in the absence of free divalent cations (5). Complement was divided into small aliquots (300 ul), stored at -70'C, and used only once after thawing. Cytotoxic test. Unless otherwise stated, the eosin exclusion test was used with both cultured human lymphoid cells (17) and peripheral lymphocytes (18) . Cold lymphocytotoxic antibodies were tested for by performing the test against cultured human lymphoid cells was significantly higher than against peripheral lymphocytes (x= 32.9, P < 0.0001). (Fig. 1 Table II . These results, together with the inability of partially purified serum HL-A antigens and of platelet suspensions from a panel of 70 donors having all known HL-A specificities to inhibit the activity of cytotoxic antibodies against cultured human lymphoid cells, exclude any clearly defined HL-A specificity of these cytotoxic antibodies. Purified p2-microglobulin also could not inhibit these cytotoxic antibodies that, however, were inhibited by antigens solubilized from cultured lymphoid cells that reacted with these antibodies in the cytotoxic test (Fig. 2) . In addition, no relationship was observed between the reactivity of cultured human lymphoid cells and presence of fi-microglobulin on the cell surface, type of immunoglobulins secreted, type of C3 receptors, or source of the cells. The titers of cytotoxic antibodies present in transplant recipients' sera varied from cell line to cell line between 1:8 and 1:256. To investigate whether the cytotoxic antibodies detected in prospective recipients of kidney transplant were directed against Epstein-Barr virus-related antigens, cultured human lymphoid cells in which the expression of these antigens was induced by treatment with 5-bromodeoxyuridine were utilized as targets in the cytotoxic test. Cells RAJI-BU were not reactive with sera positive to the parental cell line, while cells NC37-BU acquired the reactivity with sera negative to the parental cell line.
To determine the requirements of these cytotoxic antibodies for complement, their cytotolytic potential was determined by reacting them with either rabbit, guinea pig, or human complement (Fig. 3) . In this regard, these antibodies resembled HL-A antibodies because rabbit serum was the most effective source of complement. It has recently become apparent that activation of complement can be achieved through two pathways (21-23): one, the classical pathway, utilizes all nine known complement components and requires both calcium and magnesium ions. The other, the alternate pathway, activates complement at the level of C3 and uses the late-acting components, while by passing C1, 4, and 2, requiring magnesium but not calcium (24) . All the antibodies used in this study activated the classical pathway of the complement system, as lysis of target cells was prevented by treatment of complement with EGTA at a final concentration of 10 mM (Fig. 3) ; under our experimental conditions EGTA depleted the reaction mixture of calcium but not of magnesium.
Since previous work with peripheral lymphocytes had shown that prolongation of incubation time increased the sensitivity of the lymphocytotoxic test, we prolonged the incubation time from 2 to 4 h and tested sera from all prospective recipients against the panel of cultured lymphoid cells. The frequency of positive reactions increased but did not correlate with the outcome of transplants. Also, the determinations of cytotoxic antibodies reacting with cultured human lymphoid cells in the cold did not correlate with the results of the transplants. 27 of the sera from patients who later rejected the transplants were tested against cultured human lymphoid cells and peripheral lymphocytes from 50 unrelated subjects; in the latter group, either the reaction was boosted by the addition of sublytic amounts of rabbit antihuman lymphocyte serum (ALS test) or the incubation time was prolonged to 4 h (long test). As shown in Table III , of these 27 sera, 5 reacted with cultured lymphoid cells in a standard cytotoxic test, 7 with peripheral lymphocytes in the ALS test, and 2 in the long test. Considering the sera individually, three reacted with cultured lymphoid cells but not with peripheral lymphocytes, two reacted with cultured lymphoid cells and in the ALS test, two did not react with cultured lymphoid cells but reacted both in the ALS and in the long test and, finally, one serum reacted only in the ALS test
DISCUSSION
The present investigation has shown that cultured human lymphoid cells can be used to detect humoral sensitization in some prospective recipients of kidney transplants. 24% of recipients who rejected the kidney transplants had prior cytotoxic antibodies that reacted with cultured human lymphoid cells, but not with peripheral human lymphocytes from at least 80 unrelated individuals. Studies in progress by Drs. Ting and Terasaki indicate that some of these sera can trigger the killing of target cells in the antibody-mediated lympholysis test. Some sera that were positive to cultured human lymphoid cells did not react with peripheral lymphocytes from 50 unrelated donors, even when the sensitivity of the cytotoxic test was increased by either prolonging the incubation time or by adding sublytic amounts of ALS to the reaction mixture. These data suggest that the antibodies may be directed to antigens not expressed on peripheral lymphocytes, or antigens may be present in so low a density that they cannot activate the complement system after combining with antibodies.
The cytotoxic antibodies detected preoperatively in subsequent recipients of kidney transplants were not directed against HL-A antigens, because reactivity of the sera with cultured lymphoid cells did not correlate with their HL-A antigenic profile. Furthermore, the cytotoxicity of the sera could not be inhibited by platelets from a panel of donors bearing all the known HL-A specificities. ferent. The nature of these antigenic receptors is not clear at the present time, although they do not appear to be related to the presence of P.-microglobulin on the cell surface, the type of immunoglobulin secreted, the type of C3 receptors, or the source of the cells. The possibility that they may be membrane antigens related to the Epstein-Barr virus must be considered, since some sera did not react with the cell line NC37 but did react with the sublime, in which the expression of Epstein-Barr virus-related membrane antigens was induced by 5-bromodeoxyuridine (25) .
Antibodies detected in future transplant recipients can mediate lysis of lymphoid cells only in conjunction with rabbit complement and through the activation of the classical pathway of the complement system, as lysis was prevented by the selective binding of calcium. In this property these antibodies are similar to HL-A alloantibodies, which are able to activate the classical, the alternate, or both pathways of the human complement system (26), but which can only activate the classical pathway of rabbit complement (27) . Since neither the antibodies of patients who rejected their transplants by immunologic mechanisms nor the antibodies of recipients with successful grafts were able to activate human complement in vitro, it was impossible to determine if there was any difference in the pathway of complement activation that might explain the different outcomes of the transplants.
The experimental data recently reported by Morris and Dumble (28) and those obtained in this study indicate that screening sera from prospective recipients of transplants with a panel of cultured human lymphoid cells can improve the selection of patients and reduce the risk of graft rejection. Even if other investigators confirm these data in a large series of patients, two reservations should be kept in mind when considering the possible biological roles of these antibodies in the pathogenic mechanism of kidney transplant rejection: first, these antibodies cannot mediate lysis of human lymphoid cells in conjuction with human complement but require the concomitant presence of natural antibodies against human lymphoid cells present in rabbit complement (5); second, in the reactivity requirement of complement and activation of the complement system, no difference exists between cytotoxic antibodies detected in sera from patients who rejected the graft by immunological mechanisms and from patients who had favorable graft outcomes. Unfortunately, the limited amounts of available sera kept us from determining the immunoglobulin class of these antibodies.
From the practical standpoint some considerations seem to be warranted: previous studies (29) have shown that some cultured human lymphoid cells change in their susceptibility as they move through the growth cycle. 
